Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 1/20 | 0.56 |
| ▸ | AR | P10275 | 8/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9754581 | 0.83 | PRKCZ (0.60) | PRKCZARMAPTMAPK1ALDH1A1 | |
| SCHEMBL2167397 | 0.83 | PRKCZ (0.54) | PRKCZMAPTALDH1A1GAARAB9A | |
| SCHEMBL2167279 | 0.83 | POLB (0.42) | PRKCZARMAPTMAPK1ALDH1A1 | |
| SCHEMBL7640668 | 0.76 | MAPT (0.57) | PRKCZARMAPTGAARAB9A | |
| SCHEMBL11518208 | 0.71 | PRKCZ (1.00) | PRKCZARMAPTMAPK1ALDH1A1 | |
| SCHEMBL28362521 | 0.71 | KCNJ1 (0.64) | PRKCZARMAPTALDH1A1GAA | |
| SCHEMBL2168401 | 0.70 | ALDH1A1 (0.45) | MAPTMAPK1ALDH1A1GAARAB9A | |
| SCHEMBL9874545 | 0.70 | PRKCZ (0.54) | PRKCZARMAPTMAPK1ALDH1A1 | |
| SCHEMBL276323 | 0.70 | AR (0.56) | PRKCZARMAPTGAARAB9A | |
| SCHEMBL17126932 | 0.70 | AR (0.47) | PRKCZARMAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2243805-B1 | ANTHRAPYRIDONE COMPOUND OR SALT THEREOF, MAGENTA INK COMPOSITION CONTAINING THE ANTHRAPYRIDONE COMPOUND, AND COLORED BODY | NIPPON KAYAKU KK (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-7985287-B2 | Anthrapyridone compound or a salt thereof, magenta ink composition containing the anthrapyridone compound and colored product | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2011-07-26 | — | — | US | disclosed |
| US-20100291360-A1 | Anthrapyridone Compound Or A Salt Thereof, Magenta Ink Composition Containing The Anthrapyridone Compound and Colored Product | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2010-11-18 | — | — | US | disclosed |
| EP-2243805-A1 | ANTHRAPYRIDONE COMPOUND OR SALT THEREOF, MAGENTA INK COMPOSITION CONTAINING THE ANTHRAPYRIDONE COMPOUND, AND COLORED BODY | Nippon Kayaku Kabushiki Kaisha (JP) | 2010-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291360-A1 | Anthrapyridone Compound Or A Salt Thereof, Magenta Ink Composition Containing The Anthrapyridone Compound and Colored Product | MLLT3, MLLT1, H1-3 | PRKCZ 4539/4885AR 371/4885MAPT 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.